Has Raymond Thertulien, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,514,667 in general payments to Raymond Thertulien, MD across 1,027 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Raymond Thertulien, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Raymond Thertulien, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Raymond Thertulien, MD

Hematology · Charlotte, NCNPI 1275759581

Payments from drug & device makers

$1,514,667in general payments, 2019–2025

Across 1,027 payments — averaging $1474.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$328K
Sanofi US Services Inc.$242K
Bristol Myers Squibb$233K
Janssen Research & Development, LLC$118K
Sanofi$115K
Karyopharm Therapeutics Inc.$93K
plus $386K from 38 others

$1,467in research payments, 2019–2025

Across 14 payments — averaging $104.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$1K
E.r. Squibb & Sons, L.L.C.$314

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(3 entities)	364	$327,631
Sanofi US Services Inc.	27	$242,089
Bristol Myers Squibb	25	$233,022
Janssen Research & Development, LLC	23	$117,776
Sanofi	117	$115,248
Karyopharm Therapeutics Inc.	10	$93,215
Takeda Pharmaceuticals U.S.A., Inc.	39	$88,613
Incyte Corporation	93	$83,347
E.r. Squibb & Sons, L.L.C.	36	$53,756
Amgen	62	$48,131
GSK	15	$25,978
Daiichi Sankyo Inc.	33	$24,295
Pfizer	37	$22,526
Trillium Therapeutics USA, LLC	1	$15,000
Janssen Scientific Affairs, LLC	12	$6,846
Jazz Pharmaceuticals Inc.	11	$5,062
AbbVie	8	$4,256
AstraZeneca(2 entities)	14	$3,287
Genentech, Inc.	1	$1,875
Beigene, Ltd.	1	$450
Merck	20	$409
Gilead(2 entities)	7	$308
Genentech USA, Inc.	17	$243
Novartis	11	$221
Adaptive Biotechnologies Corporation	2	$156
Legend Biotech USA Inc.	2	$142
Mylan Specialty L.p.	1	$125
Pharmacyclics LLC, An Abbvie Company	3	$116
Astellas Pharma US Inc	4	$81
Exelixis Inc.	5	$76
Teva Pharmaceuticals USA, Inc.	5	$62
Puma Biotechnology, Inc.	1	$44
Seagen Inc.	3	$44
Lilly USA, LLC	3	$35
EMD Serono, Inc.	2	$30
Bayer	2	$29
Boehringer Ingelheim	2	$25
Dova Pharmaceuticals	2	$23
Agios Pharmaceuticals, Inc.	1	$21
Tesaro, Inc.	1	$19
Sun Pharmaceutical Industries Inc.	1	$17
Taiho Oncology, Inc.	1	$14
Clovis Oncology, Inc.	1	$12
Portola Pharmaceuticals, LLC	1	$12

How this compares

$1,514,667 in reported general payments places this provider in the 80th percentile of 65 hematology providers in North Carolina.

See all hematology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$68,199

Medicare patients

184

Services billed

683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Charlotte

Alan Zausner SkarbnikCharlotte$9.8M
Ryan JacobsCharlotte$8.5M
Manisha BhutaniCharlotte$6.8M
Peter VoorheesCharlotte$5.6M
Earle BurgessCharlotte$3.4M
Bei HuCharlotte$1.6M
Ruben MesaCharlotte$1.6M
Michael GrunwaldCharlotte$1.5M
Nilay ShahCharlotte$1.4M
Barry PaulCharlotte$1.3M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →